SLC5A2 and hydrops fetalis: Our findings suggest that SGLT-2 inhibitors may reduce the risk of heart failure (HF) by modulating inflammatory biomarkers, with CXCL10 potentially playing a mediating role—accounting for approximately 18% of the association between SGLT-2 inhibition and HF risk.